Charleston News Online

Anemia In Chronic Kidney Disease Pipeline Insights: Emerging therapies impact the market outlook

Anemia In Chronic Kidney Disease Pipeline Insights: Emerging therapies impact the market outlook

May 07
23:00 2020
Anemia In Chronic Kidney Disease Pipeline Insights: Emerging therapies impact the market outlook

Anemia In Chronic Kidney Disease Pipeline
Several key players such as Akebia Therapeutics, GlaxoSmithKline, Astellas Pharma, FibroGen, Inc and many others are working on developing therapies for the treatment of Anemia in Chronic Kidney Disease. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.

Anemia In Chronic Kidney Disease Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease market.

Anemia is a frequent complication of chronic kidney disease (CKD) and it is associated with a decrease in the quality of life of patients, it causes an increase in morbidity and mortality and accelerates the rate of progression of CKD.

A detailed picture of the Anemia In Chronic Kidney Disease pipeline landscape is provided, which includes the disease overview and Anemia In Chronic Kidney Disease treatment guidelines.

The assessment part of the report embraces in-depth Anemia In Chronic Kidney Disease commercial assessment and clinical assessment of the Anemia In Chronic Kidney Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anemia In Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Anemia In Chronic Kidney Disease market: Pipeline

DelveInsight estimates an increase in market size, a direct consequence of increasing prevalent population of Anemia in Chronic Kidney Disease patients in the 7MM.

Expected launch of Vadadustat, Daprodustat shall fuel the growth of the market during the forecast period, i.e., 2020–2030. Several key players such as Akebia Therapeutics, GlaxoSmithKline, Astellas Pharma, FibroGen, Inc and many others are working on developing therapies for treatment of Anemia in Chronic Kidney Disease. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.

Request for sample pages.

Scope of the report

  • The Anemia In Chronic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Anemia In Chronic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Anemia In Chronic Kidney Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Anemia In Chronic Kidney Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Anemia In Chronic Kidney Disease.

Table of contents

1. Report Introduction

2. Anemia In Chronic Kidney Disease 

3. Anemia In Chronic Kidney Disease Current Treatment Patterns

4. Anemia In Chronic Kidney Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Anemia In Chronic Kidney Disease Late Stage Products (Phase-III)

7. Anemia In Chronic Kidney Disease Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Anemia In Chronic Kidney Disease Discontinued Products

13. Anemia In Chronic Kidney Disease Product Profiles

14. Anemia In Chronic Kidney Disease Key Companies

15. Anemia In Chronic Kidney Disease Key Products

16. Dormant and Discontinued Products

17. Anemia In Chronic Kidney Disease Unmet Needs

18. Anemia In Chronic Kidney Disease Future Perspectives

19. Anemia In Chronic Kidney Disease Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/